Catalyst
Monitor for further data on overall survival and additional long-term outcomes from the CROWN trial, as well as competitive responses from other ALK inhibitors.
Humanexa recommends Escalate.
Date
June 16, 2026
Phase
N/A
Status
watch
Signal score
9.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.